Chunk #20 — RESULTS — Estimating remaining time of independence

Source

Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease.

Embedded

yes

Text

donanemab would be expected to have an additional 8 months of independence in IADLs (95% CI 5–12 months, Figure 3B) in the combined population, an additional 13 months of independence in IADLs for the low/medium tau PET group (95% CI 6–24, Figure 3C), and an additional 4 months of independence in IADLs– for the high tau PET group (95% CI 1–8 months, Figure 3D).